{"id":11303,"date":"2025-10-03T11:36:08","date_gmt":"2025-10-03T11:36:08","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/hyperthermia-survival-cancer-patients\/"},"modified":"2025-10-03T17:14:29","modified_gmt":"2025-10-03T17:14:29","slug":"hipertermija-pacientu-isgyvenamumas","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/lt\/hipertermija-pacientu-isgyvenamumas\/","title":{"rendered":"Hipertermija ir v\u0117\u017eiu sergan\u010di\u0173 pacient\u0173 i\u0161gyvenamumas: Klinikiniai duomenys rodo bendro i\u0161gyvenamumo (OS) padid\u0117jim\u0105 daugiau nei 50%"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n    {\n      \"@context\": \"https:\/\/schema.org\",\n      \"@type\": \"MedicalScholarlyArticle\",\n      \"headline\": \"Hipertermija ir v\u0117\u017eiu sergan\u010di\u0173 pacient\u0173 i\u0161gyvenamumas: Klinikiniai duomenys rodo bendro i\u0161gyvenamumo (OS) padid\u0117jim\u0105 daugiau nei 50%\",\n      \"author\": {\n        \"@type\": \"Person\",\n        \"name\": \"Gologan Cristian, M.Sc.\",\n        \"jobTitle\": \"CEO\",\n        \"affiliation\": {\n          \"@type\": \"MedicalOrganization\",\n          \"name\": \"Centrum Andromedichyperthermia\"\n        }\n      },\n      \"keywords\": \"Hipertermija, Onkologija, III faz\u0117s tyrimai, i\u0161gyvenamumas, OS, Visi\u0161ka atsakomoji reakcija, CR, Glioblastoma, kasos v\u0117\u017eys, Sarkoma, gimdos kaklelio v\u0117\u017eys, kr\u016bties v\u0117\u017eys, E-E-A-T\"\n      \/* ... Schema FAQPage b\u016bt\u0173 pridedama atskirai DUK skyriui *\/\n    }\n<\/script><\/p>\n<div class=\"author-info\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Autoritetas ir Eksperti\u0161kumas (E-E-A-T): <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Pareng\u0117: <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/hyperthermia-doctor-veronica-iatan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dr. Veronica Iatan, MD, ir <\/span><\/span><\/a><a href=\"https:\/\/andromedichyperthermia.com\/cristian-gologan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cristian Gologan M.Sc<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">, Andromedichyperthermia<\/span><\/span><\/strong><\/div>\n<article>\n<header>\n<h1><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Hipertermija ir v\u0117\u017eiu sergan\u010di\u0173 pacient\u0173 i\u0161gyvenamumas: Klinikiniai duomenys rodo bendro i\u0161gyvenamumo (OS) padid\u0117jim\u0105 daugiau nei 50% specifiniais atvejais<\/span><\/span><\/h1>\n<\/header>\n<section><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kovoje su v\u0117\u017eiu, pagrindinis tikslas yra pailginti <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">bendr\u0105 i\u0161gyvenamum\u0105 (Overall Survival, OS) <\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">su minimaliu arba jokiu papildomu toksi\u0161kumu. D\u0117l savo unikali\u0173 savybi\u0173, leid\u017eian\u010di\u0173 padidinti v\u0117\u017eio l\u0105steli\u0173 jautrum\u0105 spindulinei ir chemoterapijai, <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">hipertermija (HT)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u0161\u012f tiksl\u0105 vir\u0161ijo. Duomenys i\u0161 <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/oncologic-hyperthermia-phase-3-trials\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">randomizuot\u0173 III faz\u0117s klinikini\u0173 tyrim\u0173 (RCT) ir metaanalizi\u0173<\/span><\/span><\/strong> <span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> rodo, kad hipertermijos prid\u0117jimas prie standartini\u0173 protokol\u0173 gali padidinti <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">*bendr\u0105 i\u0161gyvenamum\u0105 daugiau nei 20%, 50% ir net 100% **<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> esant agresyvioms karcinomoms. Pristatome pa\u010dius \u012ftikinamiausius \u012frodymus su tiesiogin\u0117mis nuorodomis \u012f pirmines publikacijas:<\/span><\/span><\/a><\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">1. 2 met\u0173 i\u0161gyvenamumo padvigubinimas: Glioblastoma Multiforme<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Glioblastoma Multiforme (GBM) yra agresyviausias smegen\u0173 navikas <\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/9457811\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">. Randomizuotas I\/II faz\u0117s klinikinis tyrimas<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [1] parod\u0117, kad hipertermijos prid\u0117jimas prie brachiterapijos po \u012fprastin\u0117s spindulin\u0117s terapijos tur\u0117jo dramati\u0161k\u0105 poveik\u012f v\u0117\u017eiu sergan\u010di\u0173 pacient\u0173 prognozei, ypa\u010d <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">padvigubinant 2 met\u0173 i\u0161gyvenamumo rodikl\u012f<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> :<\/span><\/span><\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Onkologinis rodiklis<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Standartinis gydymas (be HT)<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Standartinis + Hipertermija (HT)<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Santykinis poveikis (%)<\/span><\/span><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">I\u0161gyvenamumas \u2013 2 metai<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">%15<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">%31<\/span><\/span><\/td>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Santykinis OS padid\u0117jimas +107%<\/span><\/span><\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">V\u0117\u017eiu sergan\u010di\u0173 pacient\u0173 santykinis i\u0161gyvenamumo padid\u0117jimas daugiau nei 100% per 2 metus yra negin\u010dijamas hipertermijos veiksmingumo kaip papildomos v\u0117\u017eio terapijos \u012frodymas.<\/span><\/span><\/strong><\/p>\n<p><a href=\"https:\/\/www.mdpi.com\/2072-6694\/15\/3\/880\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Naujesn\u0117s metaanaliz\u0117s [2]<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> patvirtino pana\u0161i\u0105 moduliuotos RF hipertermijos (mHT) naud\u0105 naujai diagnozuotos ligos atveju, rodan\u010dios <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">1 met\u0173 i\u0161gyvenamumo rodikl\u012f 73% palyginti su 37% kontrolin\u0117je grup\u0117je<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (recidyvuojanti liga) (p = 0.0021).<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Stipr\u016bs i\u0161gyvenamumo signalai i\u0161 lyginam\u0173j\u0173 tyrim\u0173, net ir sud\u0117tingoje gliom\u0173 klinikin\u0117je aplinkoje, pagrind\u017eia HT \u012ftraukim\u0105 \u012f klinikines gaires kaip 1A lygio indikacij\u0105.<\/span><\/span><\/strong><\/p>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2. Prailgintas i\u0161gyvenamumas: Kasos v\u0117\u017eio atveju OS padid\u0117jimas daugiau nei 50%<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kasos karcinoma (KK) yra vienas i\u0161 v\u0117\u017ei\u0173 su blogiausia prognoze. Konsoliduoti klinikiniai duomenys rodo, kad hipertermija \u017eymiai kei\u010dia klinikin\u0119 eig\u0105, nuosekliai demonstruodama OS padid\u0117jim\u0105 daugiau nei 50% v\u0117\u017eiu sergantiems pacientams:<\/span><\/span><\/p>\n<ol>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2023.41.16_suppl.e16316\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">HEAT adjuvantinis randomizuotas klinikinis tyrimas (2022)<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [3]:* Resekuotinos kasos latak\u0173 adenokarcinomos atveju regionin\u0117s hipertermijos (RHT) prid\u0117jimas l\u0117m\u0117 <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">5 met\u0173 i\u0161gyvenamumo rodiklius 28.4% prie\u0161 18.7%\\* ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">*52% santykinis i\u0161gyvenamumo padid\u0117jimas<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ).<\/span><\/span><\/strong><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><a href=\"https:\/\/doi.org\/10.1038\/s41598-024-51693-5\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Integruotas lyginamasis tyrimas (2023)<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [4]:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u200b\u200b* Metastasavusio kasos v\u0117\u017eio atveju integruotas imunomoduliacinis gydymas (\u012fskaitant moduliuot\u0105 RF hipertermij\u0105, mHT) buvo nustatytas kaip \u017eymiai prana\u0161esnis u\u017e \u012fprastin\u0119 chemoterapij\u0105.<\/span><\/span>\n<p><figure id=\"attachment_11256\" aria-describedby=\"caption-attachment-11256\" style=\"width: 1010px\" class=\"wp-caption alignnone\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-11256 size-full\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT.jpg\" alt=\"Kasos v\u0117\u017eys \u2013 Bendras i\u0161gyvenamumas OS \u2013 Imunomoduliacini\u0173 terapij\u0173 (IMT) VS Chemoterapijos (CT) VS Moduliuotos RF Hipertermijos (mHT) + CT palyginimas\" width=\"1010\" height=\"850\" title=\"\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT.jpg 1010w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT-300x252.jpg 300w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT-768x646.jpg 768w\" sizes=\"auto, (max-width: 1010px) 100vw, 1010px\" \/><figcaption id=\"caption-attachment-11256\" class=\"wp-caption-text\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kasos v\u0117\u017eys \u2013 Bendras i\u0161gyvenamumas OS \u2013 Imunomoduliacini\u0173 terapij\u0173 (IMT) VS Chemoterapijos (CT) VS Moduliuotos RF Hipertermijos (mHT) + CT palyginimas<\/span><\/span><\/figcaption><\/figure><\/li>\n<li>\u00a0<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Didelis daugiacentris retrospektyvus steb\u0117jimo tyrimas<\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37398545\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [5]<\/span><\/span><\/a><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (N=217 III-IV stadijos KK pacient\u0173) palygino moduliuot\u0105 RF hipertermij\u0105 (mHT) + CT (daugiausia pagr\u012fst\u0105 gemcitabinu) su tik CT. <\/span><\/span><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u25cf Bendras i\u0161gyvenamumas (OS): OS \u017eymiai pager\u0117jo (daugiau nei PADID\u0116JO DUKART) mHT grup\u0117je (20 m\u0117nesi\u0173, palyginti su 9 m\u0117nesiais tik CT grup\u0117je, P &lt; 0.001). <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u25cf I\u0161gyvenamumas be progresavimo (PFS): PFS taip pat \u017eymiai pager\u0117jo (7 m\u0117nesiai, palyginti su 5 m\u0117nesiais, P &lt; 0.05). <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u25cf Naviko atsakas: Pacientams, gydytiems vietine RF hipertermija (mHT), buvo \u017eymiai didesnis dalinio atsako (PR) rodiklis (45%, palyginti su 24%, P = 0.0018) ir \u017eymiai ma\u017eesnis progresavimo rodiklis (PD) (4%, palyginti su 31%, P &lt; 0.01).<\/span><\/span><\/strong><\/li>\n<\/ol>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">3. Ilgalaik\u0117 III faz\u0117s dokumentacija: Mink\u0161t\u0173j\u0173 audini\u0173 sarkoma (EORTC 62961)<\/span><\/span><\/h2>\n<p><strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Randomizuotame, tarptautiniame III faz\u0117s klinikiniame tyrime (RCT), kuris yra aukso standartas,<\/span><\/span><\/span><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * <\/span><\/span><a href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">EORTC 62961\/ESHO 95<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * [5] , <\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">pacientams, kurie gavo NACT (neoadjuvantin\u0119 chemoterapij\u0105) d\u0117l mink\u0161t\u0173j\u0173 audini\u0173 sarkomos (MAS), <\/span><\/span><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9856725\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">vidutinis bendras i\u0161gyvenamumas (OS) daugiau nei padvigub\u0117jo<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> su minimaliu toksi\u0161kumu, kas l\u0117m\u0117 HT \u012ftraukim\u0105 \u012f NCCN ir ESMO gaires.<\/span><\/span><\/span><\/strong><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Tyrim\u0105 inicijavo <\/span><\/span><a href=\"http:\/\/esho.info\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Europos Hipertermin\u0117s Onkologijos Draugija (ESHO)<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ir j\u012f koordinavo Klinikum der Universit\u00e4t M\u00fcnchen, Vokietija, bendradarbiaujant su Europos V\u0117\u017eio Tyrim\u0173 ir Gydymo Organizacijos (EORTC) Mink\u0161t\u0173j\u0173 Audini\u0173 ir Kaul\u0173 Sarkomos Grupe (STBSG). Dalyvaujantys akademiniai centrai buvo Vokietijoje (6), Norvegijoje (1), Austrijoje (1) ir Jungtin\u0117se Amerikos Valstijose (1).<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Nuo 1997 m. liepos iki 2006 m. lapkri\u010dio 9 centruose buvo registruoti suaug\u0119 pacientai (am\u017eius \u226518 met\u0173), sergantys lokalizuota mink\u0161t\u0173j\u0173 audini\u0173 sarkoma (navikas \u22655 cm, 2 arba 3 laipsnio, gilus, pagal Pranc\u016bzijos Nacionalin\u0117s Kovos su V\u0117\u017eiu Centrai Federacijos [FNCLCC] klasifikacij\u0105). Tolesni veiksmai buvo nutraukti 2014 m. gruod\u017eio m\u0117n. <\/span><\/span><\/p>\n<p><span dir=\"auto\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Regionin\u0117s hipertermijos (RHT) prid\u0117jimas padidino vidutin\u012f i\u0161gyvenamum\u0105 be ligos nuo 17.4 m\u0117nesio iki 33.3 m\u0117nesio<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (HR vietin\u0117s ar tolimosios nes\u0117km\u0117s ar mirties atveju, 0.71; 95% PI, 0.55\u20130.93; <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0\u2009= 0.01;\u00a0 <\/span><\/span><\/span><a class=\"figure-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#coi170090f2\" data-tab-toggle=\".tab-nav-figure-table\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2B paveikslas<\/span><\/span><\/span><\/a><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0).<\/span><\/span><\/span><\/p>\n<p><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong>I\u0161gyvenamumas \u017eymiai pager\u0117jo tarp tyrimo grupi\u0173 NACT plius RHT grup\u0117je, kurios vidutin\u0117 trukm\u0117 buvo 15.4 met\u0173, palyginti su 6.2 met\u0173 tik NACT grup\u0117je<\/strong> (HR 0.73; 95% PI, 0.54-0.98;\u00a0<i>P<\/i>\u2009=\u20090.04;\u00a0<a class=\"figure-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#coi170090f2\" data-tab-toggle=\".tab-nav-figure-table\" target=\"_blank\" rel=\"noopener\">2C paveikslas<\/a>). <\/span><\/span><\/span><\/p>\n<p><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong>5 ir 10 met\u0173 i\u0161gyvenamumo rodikliai NACT plius RHT grup\u0117je buvo atitinkamai 62.7% (95% PI, 55.2%-70.1%) ir 52.6% (95% PI, 44.7%-60.6%)<\/strong>, palyginti su atitinkamai 51.3% (95% PI, 43.7%-59.0%) ir 42.7% (95% PI, 35.0%-50.4%) tik NACT grup\u0117je. Pacient\u0173 skai\u010dius, kurio reikia, kad b\u016bt\u0173 gauta nauda 5 ir 10 met\u0173 i\u0161gyvenamumui, buvo atitinkamai 8.8 ir 10.1. Post-hoc analiz\u0117s parod\u0117, kad pacientams, sergantiems gal\u016bni\u0173 navikais, RHT naudai 5 ir 10 met\u0173 i\u0161gyvenamumo rodikliai buvo 75.2% prie\u0161 60.8% (absoliutus skirtumas, 14.4%; 95% PI, 0.0%-29.5%) ir 68.3% prie\u0161 59.2% (absoliutus skirtumas, 9.1%; 95% PI, 0%-24.7%). Pacientams, sergantiems ne gal\u016bni\u0173 navikais, RHT naudai 5 ir 10 met\u0173 i\u0161gyvenamumo rodikliai buvo 53.5% prie\u0161 44% (absoliutus skirtumas, 9.5%; 95% PI, 0%-23.8%) ir 41.3% prie\u0161 29.9% (absoliutus skirtumas, 11.4%; 95% PI 0%-25.1%) (<a class=\"figure-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#coi170090f2\" data-tab-toggle=\".tab-nav-figure-table\" target=\"_blank\" rel=\"noopener\">2D paveikslas<\/a>). Gydymo rezultat\u0173 santrauka pateikta\u00a0<a class=\"supplement-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#note-COI170090-1\" data-tab-toggle=\".tab-nav-supplemental\" target=\"_blank\" rel=\"noopener\">2 priedo<\/a> e1 lentel\u0117je.<\/span><\/span><\/span><\/p>\n<p><span dir=\"auto\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Regionin\u0117s hipertermijos prid\u0117jimas prie neoadjuvantin\u0117s chemoterapijos \u017eymiai pagerino i\u0161gyvenamum\u0105, su absoliu\u010diu skirtumu 11.4% per 5 metus ir 9.9% per 10 met\u0173<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> lyginant su tik neoadjuvantine chemoterapija.<\/span><\/span><\/span><\/p>\n<p>&nbsp;<\/p>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">4. 1A lygio \u012frodymai i\u0161 III faz\u0117s klinikini\u0173 tyrim\u0173: Visi\u0161kos atsakomosios reakcijos (CR) ir i\u0161gyvenamumo (OS) pagerinimas<\/span><\/span><\/h2>\n<ul>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/17881144\/\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Gimdos kaklelio v\u0117\u017eys (12 met\u0173 steb\u0117jimas)<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [7]:* Olandijos giliosios hipertermijos tyrimas (III faz\u0117), atnaujintas po 12 met\u0173 steb\u0117jimo, parod\u0117 didel\u012f bendro i\u0161gyvenamumo (OS) pager\u0117jim\u0105: <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">37% RT+HT grup\u0117je prie\u0161 20% tik RT grup\u0117je<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> .<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Recidyvuojantis kr\u016bties v\u0117\u017eys (kr\u016btin\u0117s siena)<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> :* Metaanaliz\u0117<a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994\" target=\"_blank\" rel=\"noopener\">[8]<\/a> parod\u0117 <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">visi\u0161ko atsako (CR) rodiklio santykin\u012f padid\u0117jim\u0105 +58% prid\u0117jus HT prie pakartotinio ap\u0161vitinimo. <\/span><\/span><\/strong>\u00a0<span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dviej\u0173 at\u0161ak\u0173 tyrimuose <strong>visi\u0161kas atsakas (CR) buvo pasiektas 60.2% su RT + HT<\/strong> <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">prie\u0161 38.1% tik su RT<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0(\u0161ans\u0173 santykis 2.64, 95% pasikliautinasis intervalas [PI] 1.66\u20134.18, <\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0&lt;0.0001). Rizikos santykis ir rizikos skirtumas buvo atitinkamai 1.57 (95% PI 1.25\u20131.96,\u00a0 <\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0&lt;0.0001) ir 0.22 (95% PI 0.11\u20130.33,\u00a0 <\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P\u00a0<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> &lt;0.0001).<\/span><\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/link.springer.com\/article\/10.1007\/s00066-018-1396-x\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Tiesiosios \u017earnos v\u0117\u017eys (progresav\u0119s\/recidyvuojantis)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">[9]<\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">:<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * <\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Po 5 met\u0173 steb\u0117jimo, bendro i\u0161gyvenamumo (OS) rodikliai <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">(95.8 prie\u0161 74.5%, <\/span><\/span><\/strong><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0.045), i\u0161gyvenamumo be ligos (DFS) ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">89.1 prie\u0161 70.4%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">, <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0.027), i\u0161gyvenamumo be vietinio recidyvo ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">97.7 prie\u0161 78.7%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">, <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0.006) ir i\u0161gyvenamumo be kolostomos ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">87.7 prie\u0161 69.0%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">, <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0.016) buvo \u017eymiai geresni v\u0117\u017eiu sergan\u010di\u0173 pacient\u0173 grup\u0117je, kurios gydymui buvo prid\u0117ta hipertermija.<\/span><\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Galvos ir kaklo v\u0117\u017eys (GKV)<\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">: <\/span><\/span><\/strong><a href=\"https:\/\/doi.org\/10.7314\/apjcp.2013.14.12.7395\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Randomizuoti III faz\u0117s tyrimai<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> parod\u0117 nuosekl\u0173 5 met\u0173 OS padid\u0117jim\u0105 nuo 50% iki 68.4% (p &lt; 0.005). 5 met\u0173 i\u0161gyvenamumas be ligos (DFS) padid\u0117jo nuo 25.5% iki 51.3% (p &lt; 0.005). CR rodiklis taip pat padid\u0117jo nuo 62.8% iki 81.6%. Kitame <\/span><\/span><a href=\"https:\/\/journals.lww.com\/cancerjournal\/fulltext\/2010\/06040\/hyperthermia_with_radiation_in_the_treatment_of.16.aspx\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">III faz\u0117s tyrime[10] <\/span><\/span><\/a><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">visi\u0161kas atsakas (CR) buvo steb\u0117tas 78.6% HT grup\u0117je, palyginti su 42.4% tik spindulin\u0117s terapijos grup\u0117je<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> . Skirtumas buvo statisti\u0161kai reik\u0161mingas (&lt; 0.05).<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Auk\u0161tos rizikos piktybin\u0117 melanoma (EORTC 18951\/ESHO 1.96)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> :* Vienas <\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/7776772\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">II\/III faz\u0117s klinikinis tyrimas[11]<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> parod\u0117, kad regionin\u0117 hipertermija kartu su chemoterapija \u017eymiai pagerino bendr\u0105 i\u0161gyvenamum\u0105 net ir pacientams, sergantiems pa\u017eengusia melanoma:<\/span><\/span>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">5 met\u0173 bendras i\u0161gyvenamumas:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Bendrasis rodiklis buvo 19%.<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">5 met\u0173 i\u0161gyvenamumas pacientams, kuri\u0173 liga buvo visi\u0161kai kontroliuojama:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Padid\u0117jo iki <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">38%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> .<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2 met\u0173 aktuali vietin\u0117 kontrol\u0117 <\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">28% PRIE\u0160 <\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">46% HT grup\u0117je <\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u017dymus pager\u0117jimas (p = 0.008)<\/span><\/span><\/strong><\/li>\n<\/ul>\n<\/li>\n<li>\n<section><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u0160lapimo p\u016bsl\u0117s v\u0117\u017eys (ne raumen\u012f invazinis)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u0160lapimo p\u016bsl\u0117s v\u0117\u017eys yra viena i\u0161 1A lygio indikacij\u0173 hipertermijos prid\u0117jimui prie onkologinio gydymo.[12] Hipertermin\u0117 intravesikin\u0117 chemoterapija (HIVEC) kartu su Mitomycin C yra nusistov\u0117j\u0119s metodas, rodantis \u017eym\u0173 recidyv\u0173 rodikli\u0173 pager\u0117jim\u0105:<\/span><\/span><\/p>\n<ul>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Recidyv\u0173 suma\u017einimas: Vidutin\u0117s ir auk\u0161tos rizikos ne raumen\u012f invaziniam \u0161lapimo p\u016bsl\u0117s v\u0117\u017eiui HIVEC pasirod\u0117 es\u0105s prana\u0161esnis u\u017e standartin\u0119 kambario temperat\u016bros chemoterapijos instiliacij\u0105.<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Konsoliduoti rezultatai: Metaanaliz\u0117s ir klinikiniai tyrimai (\u012fskaitant randomizuotus tyrimus) prane\u0161\u0117 apie recidyvo rizikos suma\u017e\u0117jim\u0105 daugiau nei 30% vidutin\u0117s ir auk\u0161tos rizikos pacientams, palyginti su standartine intravesikine chemoterapija [12]<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Veiksmingumas nepavykus BCG: HIVEC yra svarbi alternatyva pacientams, kuriems standartin\u0117 BCG (Bacillus Calmette-Gu\u00e9rin) terapija buvo nes\u0117kminga arba kontraindikuotina, pagerinanti i\u0161gyvenamum\u0105 be recidyv\u0173 (RFS).<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<section>\n<h2><\/h2>\n<\/section>\n<\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">5. Saugumas ir palankus terapinis indeksas (toksi\u0161kumas)<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Svarbus III faz\u0117s dokumentacijos aspektas yra tai, kad did\u017eiulis i\u0161gyvenamumo padid\u0117jimas pasiekiamas be reik\u0161mingo sunkaus 3 ar 4 laipsnio toksi\u0161kumo padid\u0117jimo. Pavyzd\u017eiui, gimdos kaklelio v\u0117\u017eio metaanaliz\u0117s neprane\u0161\u0117 apie reik\u0161mingus skirtumus \u016bminio ar v\u0117lyvojo toksi\u0161kumo at\u017evilgiu (RR 0.99 \u016bminiam toksi\u0161kumui, RR 1.01 v\u0117lyvajam toksi\u0161kumui).<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u0160is pasteb\u0117jimas i\u0161lieka ir kitose indikacijose, sustiprindamas argument\u0105, kad HT si\u016blo pagerint\u0105 terapin\u012f indeks\u0105, leid\u017eiant\u012f pacientams geriau toleruoti sud\u0117tingus gydymo re\u017eimus ir ilgainiui m\u0117gautis geresne gyvenimo kokybe.<\/span><\/span><\/p>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">I\u0161vada: Sertifikuota i\u0161gyvenamumo strategija<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Nepriklausomai nuo to, ar tai yra <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">52% OS padid\u0117jimas (kasos v\u0117\u017eys), +17 procentini\u0173 punkt\u0173 padid\u0117jimas per 12 met\u0173 (gimdos kaklelio v\u0117\u017eys), ar i\u0161gyvenamumo padvigubinimas (glioblastoma ir mink\u0161t\u0173j\u0173 audini\u0173 sarkoma),<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> randomizuot\u0173 tyrim\u0173 dokumentacija patvirtina, kad hipertermija yra ne tik papildomas gydymas, bet ir kritinis komponentas, teigiamai kei\u010diantis v\u0117\u017eiu sergan\u010di\u0173 pacient\u0173 <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">bendro i\u0161gyvenamumo<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> eig\u0105.<\/span><\/span><\/p>\n<p style=\"text-align: center;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Jei j\u016bs\u0173 tikslas yra maksimaliai padidinti bendr\u0105 i\u0161gyvenamum\u0105, hipertermijos integravimas \u012f standartin\u012f protokol\u0105 yra moksli\u0161kai pagr\u012fstas sprendimas, kurio rezultatai rodo santykin\u012f padid\u0117jim\u0105 vir\u0161 50% kai kuriose indikacijose.<\/span><\/span><\/strong><\/p>\n<\/section>\n<footer>\n<hr \/>\n<p><small><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">E-E-A-T Garantija:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u0160is turinys yra pagr\u012fstas konsoliduotais duomenimis i\u0161 III faz\u0117s randomizuot\u0173 klinikini\u0173 tyrim\u0173 ir perspektyvi\u0173 randomizuot\u0173 tyrim\u0173, paskelbt\u0173 pripa\u017eintuose medicinos \u017eurnaluose. Pilnos nuorodos yra integruotos su saitais \u012f pirmines publikacijas.<\/span><\/span><\/small><\/p>\n<\/footer>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Nuorodos:<\/span><\/span><\/p>\n<ol>\n<li>Sneed PK, Stauffer PR, McDermott MW, Diederich CJ, Lamborn KR, Prados MD, Chang S, Weaver KA, Spry L, Malec MK, Lamb SA, Voss B, Davis RL, Wara WM, Larson DA, Phillips TL, Gutin PH. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +\/- hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Phys. 1998 Jan 15;40(2):287-95. doi: 10.1016\/s0360-3016(97)00731-1. PMID: 9457811.<\/li>\n<li>Szasz, A.M.; Arrojo Alvarez, E.E.; Fiorentini, G.; Herold, M.; Herold, Z.; Sarti, D.; Dank, M. Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas.\u00a0<em>Cancers<\/em>\u00a0<b>2023<\/b>,\u00a0<em>15<\/em>, 880. https:\/\/doi.org\/10.3390\/cancers15030880<\/li>\n<li><span class=\"hlFld-ContribAuthor\"><a title=\"articles by this author\" href=\"https:\/\/ascopubs.org\/action\/doSearch?ContribAuthorRaw=Issels%2C+Rolf+D\" target=\"_blank\" rel=\"noopener\">Rolf D. Issels et al.<\/a><\/span>Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomized clinical trial.. <i>J Clin Oncol<\/i>\u00a0<b>41<\/b>, e16316-e16316(2023).DOI:<a title=\"Link to DOI\" href=\"https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e16316\" target=\"_blank\" rel=\"noopener\">10.1200\/JCO.2023.41.16_suppl.e16316\u00a0<\/a><\/li>\n<li><span style=\"font-size: 16px;\">Kleef, R., Dank, M., Herold, M. <i>et al.<\/i>\u00a0Author Correction: Comparison of the effectiveness of integrative immunomodulatory treatments and conventional therapies on the survival of selected gastrointestinal cancer patients.\u00a0<i>Sci Rep<\/i>\u00a0<b>14<\/b>, 1129 (2024).\u00a0<\/span><\/li>\n<li>Fiorentini G, Sarti D, Mambrini A, Hammarberg Ferri I, Bonucci M, Sciacca PG, Ballerini M, Bonanno S, Milandri C, Nani R, Guadagni S, Dentico P, Fiorentini C. Hyperthermia combined with chemotherapy\u00a0<i>vs<\/i>\u00a0chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study. World J Clin Oncol. 2023 Jun 24;14(6):215-226. doi: 10.5306\/wjco.v14.i6.215. PMID: 37398545; PMCID: PMC10311475.<\/li>\n<li><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Issels RD <\/span><\/span><\/span><span class=\"al-author-delim\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">,<\/span><\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0Lindner LH\u00a0 <\/span><\/span><\/span><span class=\"al-author-delim\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">,<\/span><\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0Verweij J et al. Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes in patients with high-risk localized soft tissue sarcoma\u00a0 <\/span><\/span><\/span><span class=\"subtitle\"><span class=\"colon-for-citation-subtitle\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">:<\/span><\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0the EORTC 62961-ESHO 95 randomized clinical trial.\u00a0 <\/span><\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">JAMA Oncol.<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> 2018 ;4(4):483\u2013492. doi:10.1001\/jamaoncol.2017.4996\u00a0<\/span><\/span><\/span><\/li>\n<li>Franckena M, Stalpers LJ, Koper PC, Wiggenraad RG, Hoogenraad WJ, van Dijk JD, W\u00e1rl\u00e1m-Rodenhuis CC, Jobsen JJ, van Rhoon GC, van der Zee J. Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch Deep Hyperthermia Trial. Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1176-82. doi: 10.1016\/j.ijrobp.2007.07.2348. Epub 2007 Sep 19. PMID: 17881144.<\/li>\n<li><span class=\"title-text\"><span class=\"anchor-text-container\"><span class=\"anchor-text\"><span class=\"react-xocs-alternative-link\"><span class=\"given-name\">Niloy R.<\/span>\u00a0<span class=\"text surname\">Datta<\/span> MD, Emsad Puric MD,<\/span><\/span><\/span>\u00a0<span class=\"anchor-text-container\"><span class=\"anchor-text\"><span class=\"react-xocs-alternative-link\"><span class=\"given-name\">Dirk<\/span>\u00a0<span class=\"text surname\">Klingbiel<\/span> PhD\u00a0<\/span><\/span><\/span>, Silvia Gomez MD,\u00a0<span class=\"anchor-text-container\"><span class=\"anchor-text\"><span class=\"react-xocs-alternative-link\"><span class=\"given-name\">Stephan<\/span>\u00a0<span class=\"text surname\">Bodis<\/span> MD ,<\/span><\/span><\/span>Hyperthermia and Radiation Therapy in Locoregional Recurrent Breast Cancers: A Systematic Review and Meta-analysis<\/span>\n<div id=\"banner\" class=\"Banner\"><\/div>\n<\/li>\n<li>Ott, O.J., Schmidt, M., Semrau, S.\u00a0<i>et al.<\/i>\u00a0Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus.\u00a0<i>Strahlenther Onkol<\/i>\u00a0<b>195<\/b>, 607\u2013614 (2019). https:\/\/doi.org\/10.1007\/s00066-018-1396-x<\/li>\n<li>Huilgol, Nagraj G.; Gupta, Sapna; C. R., Sridhar. Hyperthermia with radiation in the treatment of locally advanced head and neck cancer .A report of randomized trial. <span class=\"ej-journal-name\">Journal of Cancer Research and Therapeutics <\/span><span id=\"ej-journal-date-volume-issue-pg\"><a href=\"https:\/\/journals.lww.com\/cancerjournal\/toc\/2010\/06040\" target=\"_blank\" rel=\"noopener\">6(4):p 492-496, Oct\u2013Dec 2010.<\/a><\/span><span class=\"ej-journal-doi\">DOI:\u00a0<\/span>10.4103\/0973-1482.77101<\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">[ Abstract ] Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Mella O, Bentzen SM. Randomized trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. The Lancet. 1995 Mar 4;345(8949):540-3. doi: 10.1016\/s0140-6736(95)90463-8. PMID: 7776772.<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Angulo JC, Alvarez-Ossorio JL, Dominguez-Escrig JL, Moyano JL, Sousa A, Fernandez JM, Gomez-Veiga F, Unda M, Carballido J, Carrero V, Fernandez-Aparicio T, Garcia de Jalon AA, Solsona E, Inman B, Palou JC. Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial. Eur Urol Oncol. 2023 Feb;6(1):58-66. doi: 10.1016\/j.euo.2022.10.008. Epub 2022 Nov 23. PMID:36435738.<\/span><\/span><\/span><\/span><\/li>\n<\/ol>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Autoritetas ir Eksperti\u0161kumas (E-E-A-T): Pareng\u0117: Dr. Veronica Iatan, MD, ir Cristian Gologan M.Sc, Andromedichyperthermia Hipertermija ir v\u0117\u017eiu sergan\u010di\u0173 pacient\u0173 i\u0161gyvenamumas: Klinikiniai duomenys rodo bendro i\u0161gyvenamumo (OS) padid\u0117jim\u0105 daugiau nei 50% specifiniais atvejais Kovoje su v\u0117\u017eiu, pagrindinis tikslas yra pailginti bendr\u0105 i\u0161gyvenamum\u0105 (Overall Survival, OS) su minimaliu arba jokiu papildomu toksi\u0161kumu. D\u0117l savo unikali\u0173 savybi\u0173, leid\u017eian\u010di\u0173&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[173,959,38],"tags":[569,372,570,373,367,368,823,824,366,571,371,966,822],"class_list":["post-11303","post","type-post","status-publish","format-standard","hentry","category-news-lt","category-studii-clinice-lt","category-uncategorized-lt","tag-cr-lt","tag-gimdos-kaklelio-vezys","tag-glioblastoma-lt","tag-hipertermija-lt","tag-iii-fazes-tyrimai","tag-isgyvenamumas","tag-kasos-vezys","tag-kruties-vezys","tag-onkologija","tag-os-lt","tag-sarkoma","tag-studii-faza-iii-lt","tag-visiska-atsakomoji-reakcija"],"gutentor_comment":0,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/lt\/wp-json\/wp\/v2\/posts\/11303","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/lt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/lt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/lt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/lt\/wp-json\/wp\/v2\/comments?post=11303"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/lt\/wp-json\/wp\/v2\/posts\/11303\/revisions"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/lt\/wp-json\/wp\/v2\/media?parent=11303"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/lt\/wp-json\/wp\/v2\/categories?post=11303"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/lt\/wp-json\/wp\/v2\/tags?post=11303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}